Tinengotinib
Small moleculeexperimental
Clinical trial activity
11 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
8
Phase 3
1
Phase 4
0
Earliest trial started Oct 15, 2018 (NCT03654547)
Timeline
Indications
Studied for
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Cholangiocarcinoma · Phase 3
- Gallbladder Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Mutation · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Receptors, Fibroblast Growth Factor · Phase 2
- Sarcoma · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Thyroid Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
FLT1 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1[nH]nc2c1N=C(c1ccccc1Cl)c1cnc(N3CCOCC3)cc1N2- Mol. weight
- 394.87 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314430 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07052253 | Phase 2 | Jul 25, 2025 | Akeso Pharmaceuticals, Inc., TransThera Biosciences Co., Ltd |
| NCT06457919 | Phase 1/Phase 2 (Phase 2) | Jun 4, 2024 | Memorial Sloan-Kettering Cancer Center |
| NCT06221774 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2024 | Nanjing University |
| NCT05948475 | Phase 3 | Dec 31, 2023 | TransThera Biosciences Co., Ltd, University of Texas at Houston |
| NCT06057571 | Phase 2 | Nov 7, 2023 | TransThera Biosciences Co., Ltd |
| NCT05253053 | Phase 1/Phase 2 (Phase 2) | Apr 13, 2022 | TransThera Biosciences Co., Ltd |
| NCT04919642 | Phase 2 | Oct 31, 2021 | TransThera Biosciences Co., Ltd, University of Texas at Houston |
| NCT04742959 | Phase 1/Phase 2 (Phase 2) | Jul 14, 2021 | TransThera Biosciences Co., Ltd, University of Texas at Houston |
| NCT04705922 | Phase 1 | Dec 29, 2020 | Pharmaron, TransThera Biosciences Co., Ltd |
| NCT03654547 | Phase 1 | Oct 15, 2018 | TransThera Biosciences Co., Ltd, University of Texas at Houston |
| NCT06370013 | N/A | — | TransThera Biosciences Co., Ltd |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TransThera Biosciences Co., Ltd | For profit | 9 | 8 | 4 | 2018 |
| University of Texas at Houston | Academic/Hospital | 4 | 0 | 3 | 2018 |
| Akeso Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Nanjing University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Pharmaron | For profit | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1